Biogen Inc.

Biogen Inc.

BIIB

$249.01

Updated: 03/11/2026, 13:04:47

Market Cap
$36.81B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

USD
NASDAQ
CEO: Christopher A. Viehbacher
Employees: 7,500
https://www.biogen.com
Asset Summaries
Latest generated summaries for BIIB

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
BIIB-10-k-fy2025.html4.1 MBtext/htmlENFiled 06/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 31 KPI observations

Revenue

N/A

FY — · Reported

Net income

$1.3B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$2.1B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

N/A

FY — · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Reported sales by product or service. Shares and growth are calculated from the filing values.
Product / serviceSalesShare of salesYoY growthBy reported area
ms_2025_musd
Source evidence
“Multiple Sclerosis$4,038.9 $4,349.8 $4,661.9 (7.1)%(6.7)%$(310.9)$(312.1)”
4,038.9N/AN/ANot disclosed by product and area
rare_disease_2025_musd
Source evidence
“Multiple Sclerosis$4,038.9 $4,349.8 $4,661.9 (7.1)%(6.7)%$(310.9)$(312.1)”
2,154.2N/AN/ANot disclosed by product and area
biosimilars_2025_musd
Source evidence
“Multiple Sclerosis$4,038.9 $4,349.8 $4,661.9 (7.1)%(6.7)%$(310.9)$(312.1)”
729.1N/AN/ANot disclosed by product and area
other_2025_musd
Source evidence
“Multiple Sclerosis$4,038.9 $4,349.8 $4,661.9 (7.1)%(6.7)%$(310.9)$(312.1)”
197.2N/AN/ANot disclosed by product and area

Other offerings mentioned without separate sales

Marketed product portfolio
MS product portfolio and FAMPYRA termination
SKYCLARYS early-stage European launch
Alzheimer's collaboration (LEQEMBI 50% share)
Other product category includes ZURZUVAE
LEQEMBI early-stage launch with Eisai

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Biogen business overview

Global biopharma focused on discovering, developing and delivering therapies for serious and complex diseases; advancing pipeline in neurology, specialized immunology and rare diseases.

98%
Source evidence
“Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases.”

Biogen is a biopharmaceutical company dependent on product revenue

Biopharma company substantially dependent on product revenue and anti-CD20 therapeutic program rights

95%
Source evidence
“We are substantially dependent on revenue from our products. Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs.”

U.S. and international distribution

U.S. products distributed principally via wholesale/specialty distributors and specialty pharmacies; internationally via wholesale distributors and third-party distribution partners.

95%
Source evidence
“We distribute our products in the U.S. principally through wholesale and specialty distributors of pharmaceutical products and specialty pharmacies.”

Marketed product portfolio

MS: VUMERITY, TYSABRI, TECFIDERA, AVONEX, PLEGRIDY; SPINRAZA (SMA); SKYCLARYS (FA); QALSODY (ALS); LEQEMBI (with Eisai); ZURZUVAE (with Supernus); biosimilars BENEPALI, IMRALDI, FLIXABI.

98%
Source evidence
“Our marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.”

MS product portfolio and FAMPYRA termination

MS revenue includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA; FAMPYRA collaboration and license agreement terminated effective January 1, 2025

97%
Source evidence
“MS revenue includes sales from TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA. Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.”

SKYCLARYS early-stage European launch

SKYCLARYS in early-stage launch in certain European markets

95%
Source evidence
“SKYCLARYS is in the early stages of commercial launch in certain European markets”

Alzheimer's collaboration (LEQEMBI 50% share)

Alzheimer's collaboration revenue consists of 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties

95%
Source evidence
“Alzheimer's collaboration revenue consists of our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties.”

Other product category includes ZURZUVAE

Other product revenue includes ZURZUVAE, FUMADERM and ADUHELM; grew from $82.5M (2024) to $197.2M (2025)

95%
Source evidence
“Other includes ZURZUVAE, FUMADERM and ADUHELM.”

LEQEMBI early-stage launch with Eisai

LEQEMBI in early-stage U.S./international launch, commercialized with Eisai

95%
Source evidence
“LEQEMBI is in the early stages of commercial launch in the U.S. and certain international markets”

SPINRAZA revenue by geography FY2025

U.S. SPINRAZA $625.5M, Rest of world $921.3M in 2025

95%
Source evidence
“Rest of world SPINRAZA revenue decreased $26.2 million, from $947.5 million in 2024 to $921.3 million in 2025, or 2.8%”

Product revenue by franchise FY2023-2025

MS $4,038.9M (-7.1%), Rare disease $2,154.2M (+8.4%), Biosimilars $729.1M (-8.1%), Other $197.2M (+139.0%); total $7,119.4M

99%
Source evidence
“Multiple Sclerosis$4,038.9 $4,349.8 $4,661.9 (7.1)%(6.7)%$(310.9)$(312.1)”

Total revenue and components FY2025 vs prior years

Total revenue $9,890.6M (2025) vs $9,675.9M (2024) vs $9,835.6M (2023); product revenue: US $3,547.9M, Rest of world $3,571.5M; anti-CD20 $1,860.6M; Alzheimer's collaboration $177.7M; contract manufacturing, royalty and other $732.9M

99%
Source evidence
“Total revenue$9,890.6 $9,675.9 $9,835.6 2.2 %(1.6)%$214.7 $(159.7)”

Anti-CD20 therapeutic programs revenue

Anti-CD20 therapeutic programs revenue $1,860.6M in 2025, +6.3% vs $1,749.9M in 2024

95%
Source evidence
“Revenue from anti-CD20 therapeutic programs1,860.6 1,749.9 1,689.6 6.3 3.6 110.7 60.3”

Operations and dependencies

Solothurn Switzerland biologics facility

New large-scale biologics facility in Solothurn, Switzerland is operational and approved for manufacture of LEQEMBI and TYSABRI.

97%
Source evidence
“we expanded our large molecule production capacity and built a large-scale biologics manufacturing facility in Solothurn, Switzerland. The Solothurn facility is operational and has been approved for the manufacture of LEQEMBI and TYSABRI.”

Key manufacturing facilities Solothurn and RTP

Manufacturing capacity utilization at Solothurn and RTP facilities; reliance on CMOs

90%
Source evidence
“our ability to fully utilize our manufacturing facilities, including our Solothurn and RTP facilities”

In-house drug substance manufacturing for large molecule products

Global bulk supply of large molecule products depends on Biogen's own manufacturing facilities

90%
Source evidence
“We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates.”

Reliance on third-party and single-source suppliers for manufacturing

Single-source providers of raw materials and manufacturing supplies; alternatives require significant time, expense and FDA approval

95%
Source evidence
“due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies.”

Personnel retention and organizational change risk

Organizational changes and retention of management/key personnel could disrupt business operations

80%
Source evidence
“we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company”

Positioning and strategy

Acquisitions of Reata, HI-Bio and Alcyone

Completed acquisitions of Reata, HI-Bio and Alcyone with anticipated benefits at risk

90%
Source evidence
“our ability to realize the anticipated benefits from our acquisitions of Reata, HI-Bio and Alcyone, including future performance of the SKYCLARYS product, further development of the felzartamab product and future development of drug delivery solutions”

Divestiture with $28.0M payment effective January 2026

Transaction effective January 2026; received $28.0 million payment in November 2025 and recognized minimal gain on disposal

85%
Source evidence
“we received a payment of $28.0 million in November 2025 and recognized a minimal gain on disposal”

Fit for Growth cost-reduction program

Fit for Growth cost-optimization program underway with execution risks

95%
Source evidence
“We face risks associated with our Fit for Growth program that may impair our ability to achieve anticipated savings and operational efficiencies”

Manufacturing capacity expansion and modernization

Expanding capacity via Solothurn facility and investing to modernize/automate RTP manufacturing; underutilization would trigger excess capacity charges.

94%
Source evidence
“we continue to invest to modernize, automate and support the capacity requirements for our pipeline and existing products at our existing manufacturing facilities in RTP.”

Pipeline prioritization and discontinuations

Discontinued BIIB143 (cemdomespib) for DPN in early 2025 and felzartamab open label Phase 1b lupus nephritis study in November 2025 as part of pipeline prioritization

93%
Source evidence
“In early 2025 we discontinued further development of BIIB143 (cemdomespib) for the treatment of DPN, as part of our ongoing pipeline prioritization efforts.”

Pipeline investment in felzartamab, litifilimab, salanersen

Corporate strategy includes significant investment in felzartamab, litifilimab and salanersen

90%
Source evidence
“our ability to effectively implement our corporate strategy which includes significant investment in product and pipeline candidates, including but not limited to felzartamab, litifilimab and salanersen”

Risks, financing, and outlook

Russia/Ukraine and Middle East revenue exposure

Russia/Ukraine and broader Middle East each <2.0% of total revenue (2025, 2024, 2023); no affiliates or employees in Russia or Ukraine; Russia served via a distributor.

96%
Source evidence
“Revenue generated from sales in Russia and Ukraine represent less than 2.0% of total revenue for the years ended December 31, 2025, 2024 and 2023.”

2026 MS revenue expected to decline on competition

2026 total MS revenue expected to decline due to increasing competition, TECFIDERA generic erosion in E.U., and TYSABRI biosimilar entrant; partially offset by VUMERITY demand

97%
Source evidence
“In 2026 we expect total MS revenue will continue to decline as a result of increasing competition for many of our MS products in both the U.S. and rest of world markets.”

Liquidity sufficiency outlook

Management believes existing funds and financing access are sufficient for foreseeable requirements

90%
Source evidence
“our belief that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future”

IRA drug pricing reforms

IRA drug pricing reforms: Medicare price negotiation (2026 Part D, 2028 Part B), inflation rebates, 8.0% biosimilar Part B add-on, $2,000 Part D out-of-pocket cap from 2025 with manufacturer responsibility up to 10%/20%.

96%
Source evidence
“Medicare Part D redesign which replaces the current coverage gap provisions and establishes a $2,000 cap for out-of-pocket costs for Medicare beneficiaries beginning in 2025, with manufacturers being responsible for up to 10.0% of costs up to the $2,000 cap and up to 20.0% after that cap is reached.”

IRA Medicare Part D redesign and MFN drug pricing

U.S. healthcare reform exposure including IRA Part D redesign and MFN drug pricing actions

95%
Source evidence
“the impact of the IRA Medicare Part D redesign, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products, as well as the potential impact of legislative and regulatory changes and priorities, including actions related to MFN drug pricing”

cGMP compliance and inspection risk

cGMP noncompliance at own or third-party facilities could trigger penalties, sanctions and supply impairment

90%
Source evidence
“We and our third-party providers are required to maintain compliance with cGMP and other stringent requirements, as applicable, and are subject to inspections by the FDA and other regulatory authorities to confirm compliance.”

TECFIDERA generic erosion and EPO patent revocation

Multiple TECFIDERA generics in North America, Brazil and certain European countries; TECFIDERA revenue expected to continue declining; EPO revoked EP 2 653 873 in November 2025.

97%
Source evidence
“In November 2025 the Technical Boards of Appeal of the European Patent Office revoked our EP 2 653 873 patent related to TECFIDERA, after which we stopped enforcing this patent and its national counterparts.”

Tariff and trade policy exposure

Tariffs/trade tensions (incl. Section 232 pharma investigation) create uncertainty; company does not expect currently applicable tariffs to have a material adverse effect on 2026 operations.

96%
Source evidence
“As of the date of this filing, we do not expect the tariffs currently applicable to our business to result in a material adverse effect on our operations in 2026.”

Biosimilar and generic competition

TYSABRI biosimilar approved in U.S. and E.U. in 2023; multiple TECFIDERA generic entrants driving revenue decline

96%
Source evidence
“a biosimilar entrant of TYSABRI was approved in the U.S. and the E.U. in 2023. We expect that future sales of TYSABRI will continue to be adversely affected by the entrance of this biosimilar worldwide.”

TYSABRI biosimilar competition

A TYSABRI biosimilar was approved in the U.S. and E.U. in 2023; TYSABRI sales expected to continue being adversely affected.

96%
Source evidence
“A biosimilar entrant of TYSABRI was approved in the U.S. and the E.U. in 2023. We expect the future sales of TYSABRI will continue to be adversely affected by the entrance of this biosimilar.”

Pricing and reimbursement dependency

Sales substantially depend on payer coverage, pricing and reimbursement

95%
Source evidence
“Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations”

Cybersecurity and information systems breach risk

Breakdown or breach of information systems and cloud technologies could subject Biogen to liability, ransom payments and operational interruption

95%
Source evidence
“A breakdown or breach of our information systems could subject us to liability or interrupt our business operations.”

Biosimilar/generic competition erosion

Revenue at risk from TECFIDERA generics and TYSABRI biosimilar entrant

95%
Source evidence
“increased competition from TECFIDERA generic entrants and a biosimilar entrant of TYSABRI”

Data privacy regulation exposure (GDPR, CCPA)

Non-compliance with GDPR, CCPA and evolving privacy/security regulations may result in fines, litigation and enforcement actions

90%
Source evidence
“the E.U.'s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance.”

Tariffs and trade restrictions as supply chain cost/driver

Tariffs, trade restrictions and geopolitical instability could disrupt manufacturing, cause product shortages and increase costs

90%
Source evidence
“imposition of tariffs or trade restrictions, power failures, cyber-attacks and other supply chain disruptions could result in difficulties and delays in manufacturing our products”

Product loss and manufacturing contamination risk

Manufacturing susceptible to product loss from contamination, oxidation and equipment failure; contamination may require extended facility closure

90%
Source evidence
“If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.”

Tariffs and trade restrictions

Exposure to newly imposed U.S. tariffs and responsive non-U.S. tariffs

90%
Source evidence
“the impact of new laws, regulatory actions, judicial decisions, accounting standards and tariffs or trade restrictions, including any newly imposed U.S. tariffs and any responsive non-U.S. tariffs applicable to our products or operations”

Geopolitical tensions: US-China, Russia-Ukraine, Middle East

Geopolitical tensions impact operations, sales and clinical trial activities

90%
Source evidence
“tensions between the U.S., and China and other countries, regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East”

Cybersecurity and AI-related risks

Cybersecurity incident risk and risks from incorporating AI into processes

90%
Source evidence
“our use of information technology systems and data and the potential impacts of any breakdowns, interruptions, invasions, corruptions, data breaches, destructions and/or other cybersecurity incidents of such systems or those of our business partners”

Collaborator dependence on Eisai and Supernus

Dependence on collaborators including Eisai and Supernus for product development and commercialization

90%
Source evidence
“including collaborations with third parties including but not limited to Eisai and Supernus, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators' products”

AI-based software usage risk

Increasing use of AI-based software across R&D, manufacturing and commercialization presents legal, reputational and cybersecurity risks

90%
Source evidence
“AI-based software is increasingly used in the biopharmaceutical industry, including by us, for research, marketing, manufacturing and commercialization, and we anticipate increasing our usage of technology that uses AI in the future.”

Product safety, labeling and regulatory scrutiny risk

Safety warnings or restrictions on product labels may significantly reduce expected revenue; adverse events may trigger withdrawal or penalties

85%
Source evidence
“Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products or require significant expense or divert management time.”

Material exposure graph

Two wholesale distributors
Customer Exposure

Two wholesale distributors each exceed 10% of total revenue and combined account for ~43.9% of 2025 gross product revenue, creating significant customer concentration.

Relevance 92·Dependency 90·Confidence 98
Source evidence
“on a combined basis, accounted for approximately 43.9%, 39.3% and 36.9%, respectively, of our gross product revenue”
TECFIDERA
Competitive Exposure

Multiple generic entrants drove TECFIDERA revenue down 29.7% to $679.7M in 2025, with further E.U. generic acceleration expected in 2026.

Relevance 92·Dependency 75·Confidence 96
Source evidence
“driven by a decrease in global demand as a result of multiple TECFIDERA generic entrants”
LEQEMBI
Revenue Exposure

Biogen is substantially dependent on product revenue, and LEQEMBI launch success (with Eisai) is a key growth driver; reimbursement and commercial strategy risks directly affect revenue.

Relevance 90·Dependency 75·Confidence 90
Source evidence
“Biogen's and Eisai's ability to successfully commercialize LEQEMBI and our ability to successfully commercialize SKYCLARYS may be adversely affected”
TYSABRI
Competitive Exposure

TYSABRI biosimilar entrants in Europe and worldwide expected to continue eroding sales of a $1.67B product.

Relevance 88·Dependency 65·Confidence 95
Source evidence
“primarily due to increased competition in rest of world, including the impacts from a biosimilar entrant of TYSABRI in Europe”
Government and private payers
Demand Driver

Product sales depend heavily on coverage, pricing and reimbursement decisions by governmental health authorities and private insurers subject to political and competitive pressure.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations”
Single source raw materials and manufacturing supplies
Supplier Dependency

Biogen depends on single-source providers for certain raw materials and supplies; replacement is time-consuming, costly and requires regulatory approval, creating product supply risk.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies.”
Biogen manufacturing facilities
Manufacturing Dependency

Global bulk supply of large molecule drug substance depends on uninterrupted operation of company facilities, exposed to failures, shortages, disasters and cyber-attacks.

Relevance 85·Dependency 75·Confidence 90
Source evidence
“Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities”
SKYCLARYS
Revenue Exposure

SKYCLARYS is in early-stage European launch, dependent on Biogen obtaining and maintaining reimbursement; the acquisition of Reata's anticipated benefits hinge on SKYCLARYS performance.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“Biogen's ability to obtain and maintain adequate reimbursement for SKYCLARYS”
IRA
Regulatory Exposure

IRA drug price negotiation and Medicare Part D redesign, plus MFN drug pricing actions, create pricing/reimbursement pressure on Biogen's products.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“including those relating to any future potential drug price negotiation under the IRA or other legislative or executive acts”
TECFIDERA
Revenue Exposure

Multiple generics with deeply discounted prices have significantly reduced TECFIDERA revenue, and continued decline is expected; EPO patent revocation intensifies exposure.

Relevance 85·Dependency 60·Confidence 97
Source evidence
“The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline.”
Eisai
Technology Dependency

LEQEMBI is jointly commercialized with Eisai, whose reimbursement success, commercial strategy and strategic stability materially affect Biogen's Alzheimer's revenue.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“Eisai's ability to obtain and maintain adequate reimbursement for LEQEMBI”
current Good Manufacturing Practices (cGMP)
Regulatory Exposure

Failure of own or third-party facilities to maintain cGMP compliance or pass FDA inspections could impair product development, commercialization and trigger sanctions.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA Medicare price negotiation, inflation rebates and Part D redesign may significantly impact U.S. pharmaceutical pricing and Biogen's revenue.

Relevance 80·Dependency 65·Confidence 95
Source evidence
“The IRA also contains substantial drug pricing reforms that may have a significant impact on the pharmaceutical industry in the U.S.”
VUMERITY
Demand Driver

VUMERITY revenue grew 18.9% to $746.8M on global demand and is expected to partially offset MS portfolio declines in 2026.

Relevance 80·Dependency 55·Confidence 93
Source evidence
“We expect the decline to be partially offset by continued increasing demand for VUMERITY.”
TYSABRI
Competitive Exposure

A biosimilar approved in the U.S. and E.U. in 2023 is expected to continue adversely affecting TYSABRI sales.

Relevance 78·Dependency 55·Confidence 96
Source evidence
“We expect the future sales of TYSABRI will continue to be adversely affected by the entrance of this biosimilar.”
Cybersecurity threats
Legal Exposure

Increasing cyber threats, including ransomware and supply chain attacks, could cause liability, ransom payments, IP loss and business interruption; liability insurance may be insufficient.

Relevance 75·Dependency 65·Confidence 95
Source evidence
“Cybersecurity threats and incidents are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect”
Tariffs / U.S.-China trade tensions
Geopolitical Exposure

U.S. baseline tariffs, China-related tariffs and a Section 232 pharma import investigation create cost and supply chain uncertainty, though no material 2026 impact is currently expected.

Relevance 75·Dependency 60·Confidence 95
Source evidence
“The U.S. Secretary of Commerce has further initiated an investigation to determine the effects on the national security of imports of pharmaceuticals and pharmaceutical ingredients... under Section 232 of the Trade Expansion Act of 1962.”
SPINRAZA
Revenue Exposure

SPINRAZA (rare disease) revenue totaled ~$1.55B across US and rest of world, with softening demand partially offset by pricing and shipment timing.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“U.S. SPINRAZA revenue decreased $0.2 million, from $625.7 million in 2024 to $625.5 million in 2025 as lower demand was mostly offset by an increase in pricing and timing of shipments”
Product safety and labeling regulation
Demand Driver

Adverse safety events or required label warnings/restrictions could reduce product revenue, trigger market withdrawal, fines or criminal penalties and damage confidence in products.

Relevance 70·Dependency 60·Confidence 85
Source evidence
“Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products”
Geopolitical risk
Geopolitical Exposure

US-China tensions, Russia-Ukraine war and Middle East conflict could disrupt operations, sales and clinical trial activities.

Relevance 70·Dependency 55·Confidence 85
Source evidence
“the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension”
IRA redesign
Regulatory Exposure

IRA redesign charges partially offset VUMERITY's favorable rebate/discount estimate change in the U.S.

Relevance 70·Dependency 50·Confidence 85
Source evidence
“partially offset by charges related to the IRA redesign”
Solothurn facility
Supplier Dependency

Ability to fully utilize Solothurn and RTP manufacturing facilities and reliance on third-party contract manufacturing organizations create global bulk supply risk.

Relevance 65·Dependency 60·Confidence 85
Source evidence
“our ability to fully utilize our manufacturing facilities, including our Solothurn and RTP facilities”
LEQEMBI
Revenue Exposure

Alzheimer's collaboration revenue of $177.7M in 2025 reflects Biogen's 50% share of LEQEMBI revenue and cost of sales, a growing new revenue stream.

Relevance 65·Dependency 40·Confidence 90
Source evidence
“Alzheimer's collaboration revenue consists of our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties.”
Tariffs and trade restrictions
Geopolitical Exposure

Tariffs and trade restrictions, alongside geopolitical instability, could delay manufacturing, cause product shortages, inventory write-offs and increased costs.

Relevance 60·Dependency 50·Confidence 90
Source evidence
“imposition of tariffs or trade restrictions, power failures, cyber-attacks and other supply chain disruptions could result in difficulties and delays in manufacturing our products”
AI-based software
Technology Dependency

Biogen uses AI in research, marketing, manufacturing and commercialization and plans increased usage; flawed analyses or regulatory noncompliance could cause competitive, legal and reputational harm.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“AI-based software is increasingly used in the biopharmaceutical industry, including by us, for research, marketing, manufacturing and commercialization”
EU General Data Protection Regulation (GDPR)
Regulatory Exposure

GDPR imposes data handling requirements with large penalties for noncompliance, alongside CCPA and evolving privacy laws.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“the E.U.'s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance.”
Interferon
Demand Driver

Interferon revenue declining as patients transition to higher efficacy therapies, a secular erosion trend for legacy MS franchise.

Relevance 55·Dependency 35·Confidence 90
Source evidence
“driven by a decrease in demand as patients transition to higher efficacy therapies”
Full company information
Latest profile, trading, valuation, and identifier data stored for BIIB.
Share price
$249.01
Market cap
$36.81B
Exchange
NASDAQ
Currency
USD
CEO
Christopher A. Viehbacher
Employees
7,500
IPO date
17/09/1991
Beta
0.171
Last dividend
$0.00
Day range
$247.91 – $255.53
52-week range
$148.51 – $258.78
1-day performance
-1.82%
1-year performance
67.67%
Current drawdown (1Y)
-3.78%
CIK
0000875045
CUSIP
09062X103
ISIN
US09062X1037
Created
07/12/2025, 03:00:01
Last update
03/11/2026, 13:04:47

Track Biogen Inc. with an AI analyst

See which prediction-market events move BIIB, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BIIB from your Railway `news_articles` table.

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

PRNewsWire • STOCK • 08/06/2026, 11:00:00

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Zacks Investment Research • STOCK • 05/06/2026, 15:05:19

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

Business Wire • STOCK • 04/06/2026, 22:58:00

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

GlobeNewsWire • STOCK • 04/06/2026, 09:30:00

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

GlobeNewsWire • STOCK • 04/06/2026, 03:00:00

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

GlobeNewsWire • STOCK • 03/06/2026, 09:30:00

Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?

Zacks Investment Research • STOCK • 29/05/2026, 14:32:08

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Zacks Investment Research • STOCK • 29/05/2026, 12:55:34

Biogen (NASDAQ: BIIB) Stock Target Raised by RBC Capital Amidst Pipeline Challenges

Market Data • Market Data • 27/05/2026, 13:17:32

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

Reuters • STOCK • 27/05/2026, 04:27:10

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

GlobeNewsWire • STOCK • 26/05/2026, 18:50:00

Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)

Seeking Alpha • STOCK • 26/05/2026, 10:11:55